Andrew J. Pollard

Research interests

Publications

• The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis

  The Lancet Regional Health - Americas · 2023 · https://doi.org/10.1016/j.lana.2023.100561

• SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

  Cell · 2022 · https://doi.org/10.1016/j.cell.2021.12.046

• Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

  Cell · 2022 · https://doi.org/10.1016/j.cell.2022.06.005

• Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

  Cell · 2022 · https://doi.org/10.1016/j.cell.2022.05.014

• Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

  Cell · 2021 · https://doi.org/10.1016/j.cell.2021.10.011

• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

  The Lancet HIV · 2021 · https://doi.org/10.1016/s2352-3018(21)00103-x

• Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

  Cell · 2021 · https://doi.org/10.1016/j.cell.2021.02.037

• Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial

  The Lancet Global Health · 2021 · https://doi.org/10.1016/s2214-109x(21)00346-6

• Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2102214

• Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

  Nature Communications · 2021 · https://doi.org/10.1038/s41467-021-25167-5

• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00432-3

• Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)01124-7

• T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

  Nature Communications · 2021 · https://doi.org/10.1038/s41467-021-21856-3

• Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

  Cell · 2021 · https://doi.org/10.1016/j.cell.2021.06.020

• T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-01194-5

• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31604-4

• Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

  The Lancet Infectious Diseases · 2020 · https://doi.org/10.1016/s1473-3099(20)30634-4

• Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-01179-4

• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32661-1

• Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study

  The Lancet Infectious Diseases · 2019 · https://doi.org/10.1016/s1473-3099(19)30297-x

• Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency

  Journal of Clinical Investigation · 2017 · https://doi.org/10.1172/jci90727

• Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

  JAMA · 2016 · https://doi.org/10.1001/jama.2016.4218

• Ribosomal Protein SA Haploinsufficiency in Humans with Isolated Congenital Asplenia

  Science · 2013 · https://doi.org/10.1126/science.1234864

• A CD8+ T cell transcription signature predicts prognosis in autoimmune disease

  Nature Medicine · 2010 · https://doi.org/10.1038/nm.2130

Current projects

No projects listed.